Top Metabolomics Companies

Metabolomics Market size was valued at USD 4.67 Billion in 2024 and is poised to grow from USD 5.31 Billion in 2025 to USD 14.95 Billion by 2033, growing at a CAGR of 13.8% during the forecast period (2026–2033).

The global metabolomics industry displays a competitive landscape driven by the presence of both the prominent players and growing companies. Major firms maintain a competitive presence with a wide range of metabolomics instruments, software and services. Moreover, academic and research institutes play a large role within the metabolomics space by creating (novel) metabolomics technologies and methodologies as well as collaborations with industry. Increasing number of startups offering niche metabolomics specific tools and services are also gaining traction in the market, increasing the level of competition and driving growth. In addition, due to the global nature of the market, it is also regional in nature with players focusing on specific geographic preferences and regulations. 'Agilent Technologies, Inc. (US)', 'Thermo Fisher Scientific, Inc. (US) ', 'Waters Corporation (US) ', 'Bruker Corporation (US) ', 'Shimadzu Corporation (Japan) ', 'Danaher Corporation (SCIEX) (US) ', 'PerkinElmer, Inc. (US) ', 'Merck KGaA (Germany) ', 'Bio-Rad Laboratories, Inc. (US) ', 'Metabolon, Inc. (US) ', 'LECO Corporation (US) ', 'Human Metabolome Technologies, Inc. (Japan) ', 'GL Sciences, Inc. (Japan) ', 'Bioocrates Life Sciences AG (Austria) ', 'BASF SE (Germany) ', 'MS-OMICS (Various locations) ', 'Afekta Technologies Ltd. (Finland) ', 'DNA Xperts Private Limited. (India) ', 'Metabolomic Technologies Inc. (Canada) ', 'Kore Technology Ltd. (UK)'

Metabolite profiling in biological matrices is a key approach to biomarker discovery and personalized medicine. These metabolomics studies participate in the identification of several biomarkers which involve complex clinical phenotypes using diverse biological systems. This contributes to the development of individualized medicine for action efficiency and toxicity rectification.  

Growing Application of Biomarkers: Bioinformatics tools allow the identification of new biomarkers based on changes in human physiology highlighted by metabolomics results. Biomarkers have the utility for in-vitro diagnostics, environmental toxicology screening and drug discovery and development platform methods. Over the past decade, the omics revolution has amplified metabolomics usages in biomedical fields.

According to metabolomics market analysis, North America is dominating with the largest metabolomic market share. The region has a well-developed healthcare infrastructure, including prominent research institutions, biotechnology and life science companies, and academic centers. This platform enables high-end, leading-edge research and development in metabolomics through next-generation technologies and approaches. There are large investments in biomedical research in North America, especially government funding but also from the private sector. Such investments fuel an ongoing innovation cycle in metabolomics, which creates new biomarkers, diagnostics and therapeutic approaches. The focus on personalized medicine and precision healthcare in the region is another driver for the uptake of metabolomics technologies. Metabolomics is essential for the comprehension of disease mechanisms, for biomarker discovery and also to address individualized treatment strategies.